Skip to content

Clinical application of Tramadol hydrochloride combined with ultrasonic-guided erector spinalis plane block to prevent pain after abdominal operation in children

Clinical application of Tramadol hydrochloride combined with ultrasonic-guided erector spinalis plane block to prevent pain after abdominal operation in children

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300068775
Enrollment
Unknown
Registered
2023-02-28
Start date
2023-03-01
Completion date
Unknown
Last updated
2023-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multimodal analgesia of pain after abdominal surgery in children

Interventions

Group T:10min after induction of anesthesia, 1mg/kg tramadol hydrochloride was injected intravenously
Group TE:10min after induction of anesthesia, 1mg/kg tramadol hydrochloride and ESPB were injected intravenously
Group C:No drugs or nerve blocks were administered

Sponsors

Nanjing Maternal and Child Health Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
5 Years to 12 Years

Inclusion criteria

Inclusion criteria: The American Society of Anesthesiologists (ASA) score was grade I to II, with 5 < 12 years of age, 15 < 30kg of body weight, and 0.5 ~ 2.0h of surgery.

Exclusion criteria

Exclusion criteria: 1. Children with absolute contraindications to single-cavity tracheal intubation and malignant hyperthermia susceptibility;2. Children with heart, lung, liver and kidney insufficiency;3. Children with severe infection, dehydration, electrolyte disturbance and shock;4. Children with neuromuscular system diseases;5. Infection and scar 2 to 4cm apart from the median line of the spine of T12-L3;6. Allergic history of amides local anesthetics and central analgesics;7. Chronic pain history, long-term use of various analgesics, severe brain injury, confusion, respiratory depression;8. People who are using monoamine oxidase inhibitors, or who are prone to drug abuse or dependence;9. Children who had participated in other clinical trials or were participating in other clinical trials within 3 months before enrollment;10. Children who, in the judgment of the physician responsible for the study, may be at increased risk for the subject or may not have adequate data from the study.

Design outcomes

Primary

MeasureTime frame
IL-1ß protein concentration;TNF-a protein concentration;IL-4 protein concentration;IL-10 protein concentration;

Secondary

MeasureTime frame
Mean arterial pressure;Heart rate;

Countries

China

Contacts

Public ContactHuiying Zhang

Nanjing Maternal and Child Health Hospital

279763402@qq.com+8613851690367

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026